Compare GDC & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | NXL |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.5M |
| IPO Year | N/A | 2022 |
| Metric | GDC | NXL |
|---|---|---|
| Price | $1.45 | $4.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 76.3K |
| Earning Date | 04-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.01 | $0.22 |
| 52 Week High | $8.18 | $7.69 |
| Indicator | GDC | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 63.18 |
| Support Level | $1.32 | $4.51 |
| Resistance Level | $2.07 | $7.69 |
| Average True Range (ATR) | 0.18 | 0.44 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 28.55 | 64.43 |
GD Culture Group Ltd operates and manages its business as a single segment and has one operating and reportable segment, the Virtual Content Production. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.